Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHARE: 6 vs 12 Months of Adjuvant Herceptin in Breast Cancer
NCT00381901Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- May 2006
- Primary completion
- May 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Disease-Free Survival at 5 years. Started May 2006; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00381901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381901.